Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 51.82

-0.7%

2:28 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (751)	3/3/2000 6:01:00 PM
From: A.J. Mullen	Read Replies (2) of 52153

I wonder if it is time to reverse the valuation process. The large pharmas have ties to small biotech that came cheaply when the biotechs were poor. Merk bought Sibia outright for a song, and all the large pharma have extensive rights in return for relatively small royalty payments. Before the run-up, some biotechs were valued by estimating the worth of each of their deals with large pharma. Has anyone considered the values of all such deals to any one pharma and then summed them? The total is likely to be substantial.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next